GH · Guardant Health, Inc.
$168.52
-2.40 (-1.40%)
At close · Aug 27
Market Cap
$22.61B
Shares
134.20M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$982.02M
+32.9%
FY2025
Net Income
-$416.28M
+4.6%
FY2025
Gross Margin
64.46%
+3.7pp
FY2025
Operating Margin
-44.53%
+15.5pp
FY2025
Diluted EPS
-$3.32
+6.7%
FY2025
Operating Cash Flow
-$184.76M
+23%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.34B – $1.36B | $1.18B | $982.02MG | $739.02MG | $563.95MG | $449.54MG | $373.65M | $286.73M | $214.38M | $90.64M | $49.84M | $25.25M | |
| — | $413.95M | $349.01M | $289.8M | $227.05M | — | — | — | — | — | — | — | |
| — | $769.16M | $633.01M | $449.22M | $336.9M | — | — | — | — | — | — | — | |
| — | — | 64.46% | 60.79% | 59.74% | — | — | — | — | — | — | — | |
| — | $375.79M | $364.19M | $347.75M | $367.19M | $373.81M | $263.22M | $149.86M | $86.29M | $50.71M | $25.56M | $10.86M | |
| — | $629.84M | $494.66M | $364.94M | $295.23M | $299.83M | $191.88M | $106.51M | $78.34M | $53.47M | $32.5M | $26.19M | |
| — | $233.79M | $211.41M | $180.12M | $155.8M | $163.96M | $206.64M | $192.77M | $61.4M | $36.19M | $36.78M | $9.92M | |
| — | $1.5M | $1.7M | $2.2M | $2.7M | $2.5M | $1.9M | $1.8M | $700K | $0 | — | — | |
| — | — | $39.74M | $42.39M | $42.88M | $35.96M | $22.27M | $16.07M | $11.41M | $7.14M | $5.21M | $3.69M | |
| — | $1.65B | $1.42B | $1.18B | $1.13B | $993.92M | $784.65M | $541.68M | $296.75M | $183.58M | $126.45M | $69.1M | |
| — | -$470.26M | -$437.25M | -$443.59M | -$564.73M | -$544.38M | -$411M | -$254.95M | -$82.37M | -$92.94M | -$76.61M | -$43.85M | |
| — | — | -44.53% | -60.02% | -100.14% | -121.1% | -110% | -88.92% | -38.42% | -102.54% | -153.71% | -173.66% | |
| — | — | -$397.51M | -$401.21M | -$521.84M | -$508.42M | -$388.73M | -$238.89M | -$70.96M | -$85.81M | -$71.41M | -$40.15M | |
| — | $4.82M | $3.9M | $2.58M | $2.58M | $2.58M | $2.58M | $4.77M | $1.18M | $1.25M | $2.7M | $3.02M | |
| — | $38.77M | $34.1M | $53.69M | $35.37M | $6.07M | $3.93M | $10.17M | $13.74M | $5.27M | $2.23M | $733K | |
| — | -$18.17M | -$10.49M | -$42.61M | $53.17M | -$12.78M | $25.18M | $3.64M | $88K | $4.7M | -$1.06M | -$1000 | |
| — | -$454.47M | -$417.54M | -$435.09M | -$478.76M | -$653.45M | -$384.47M | -$245.9M | -$69.72M | -$84.23M | -$83.21M | -$46.13M | |
| — | -$1.03M | -$1.26M | $1.28M | $685K | $1.14M | $300K | $379K | -$1.87M | $38K | $7000 | $6000 | |
| — | -$453.44M | -$416.28M | -$436.37M | -$479.45M | -$654.59M | -$384.77M | -$246.28M | -$75.65M | -$85.06M | -$83.22M | -$46.14M | |
| — | — | -42.39% | -59.05% | -85.02% | -145.61% | -102.98% | -85.89% | -35.29% | -93.85% | -166.97% | -182.74% | |
| — | -$453.44M | -$416.28M | -$436.37M | -$479.45M | -$654.59M | -$405.67M | -$253.78M | -$75.65M | -$85.06M | -$89M | -$46.14M | |
| — | -$455.28M | -$415.93M | -$437.9M | -$463.6M | -$669.35M | -$413.13M | -$252.2M | -$74.46M | -$84.61M | -$83.67M | -$46.22M | |
| USD/shares | — | -$3.50 | -$3.32 | -$3.56 | -$4.28 | -$6.41 | -$4.00 | -$2.60 | -$0.84 | — | — | — |
| USD/shares | — | -$3.50 | -$3.32 | -$3.56 | -$4.28 | -$6.41 | -$4.00 | -$2.60 | -$0.84 | — | — | — |
| shares | — | — | 125.37M | 122.75M | 111.99M | 102.18M | 101.31M | 97.5M | 90.6M | 30.4M | 12.58M | 13.05M |
| shares | — | — | 125.37M | 122.75M | 111.99M | 102.18M | 101.31M | 97.5M | 90.6M | 30.4M | 12.58M | 13.05M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $52.5M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
19.49×
Peer median 5.72×
EV/EBIT
—
Peer median 33.88×
P/E (TTM)
—
Peer median 33.44×
Peer medians compare against the 25 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $982,021,000 | $739,016,000 | $563,948,000 | $449,538,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $923,279,000 | $697,162,000 | $526,524,000 | $420,618,000 | $352,561,000 | $264,657,000 | $194,312,000 | $77,916,000 |
| Non Us | $58,742,000 | $41,854,000 | $37,424,000 | $28,920,000 | $21,092,000 | $22,073,000 | $20,063,000 | $12,723,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Oncology | $683,595,000 | $542,827,000 | $403,876,000 |
| Biopharma Data | $210,132,000 | $177,579,000 | $136,351,000 |
| Screening | $79,732,000 | $5,124,000 | $0 |
| Licensing Other | $8,562,000 | $13,486,000 | $23,721,000 |
Key facts
CIK
1576280
CUSIP
40131M109
13F (30d)
484 filings
480 filers
Visit website
Investor relations